High Ventilation Breathwork as a Psychedelic Model: Clinical and Policy Implications

High Ventilation Breathwork Induces Psychedelic-Like States Without Drugs

High ventilation breathwork (HVB) can reliably induce altered states of consciousness comparable to those produced by moderate doses of serotonergic psychedelics, according to a September 2026 study published via OpenAlex (source). In this exploratory workshop, 48 mental health professionals participated in HVB sessions and reported subjective experiences that matched the intensity of psychedelic states elicited by substances such as lysergic acid diethylamide (LSD), psilocybin, and ayahuasca. This finding suggests HVB may serve as a non-pharmacological model for studying the mechanisms underlying psychedelic therapy, potentially expanding research opportunities in settings where drug-based studies face significant regulatory barriers.

Mechanisms and Clinical Context: How HVB Mimics Psychedelic Experiences

HVB involves rapid, deep breathing patterns that alter blood gases and neural activity, producing transient changes in consciousness. The study's expert participants—licensed mental health professionals—rated the subjective intensity of HVB-induced states as comparable to those documented in clinical trials of serotonergic psychedelics. Notably, the phenomenological overlap included emotional breakthroughs and perceptual alterations, both considered core to the therapeutic effects of psychedelic-assisted therapy. The study also found that participants with higher trait openness and those who experienced emotional breakthroughs during HVB were more likely to perceive it as clinically promising. This non-obvious link between psychological traits and response to breathwork may help tailor future interventions and participant selection for both HVB and psychedelic trials.

Implications for Policy, Research, and Clinical Trial Design

HVB's ability to induce psychedelic-like states without pharmacological agents has significant implications for research and policy. Non-drug models like HVB could allow scientists to investigate the therapeutic mechanisms of altered states without the regulatory constraints imposed by controlled substances. This could accelerate basic science and pilot studies, especially in jurisdictions where psychedelic drugs remain Schedule I or otherwise restricted. Furthermore, HVB may serve as a control or comparison arm in future randomized controlled trials (RCTs) of psychedelic therapy, helping to disentangle the effects of the drug from those of the induced state itself. The study's expert panel identified internalizing disorders—such as depression and anxiety—as promising indications for HVB-based interventions, aligning with the current clinical focus of psychedelic research. Importantly, the study highlights that HVB could help democratize access to altered state therapies, particularly in settings with limited resources or legal barriers to drug-based treatments.

Risks, Contraindications, and the Need for Controlled Evidence

Despite its promise, HVB is not without risks. The expert participants identified psychotic, dissociative, and bipolar disorders as clear contraindications, echoing the exclusion criteria common in psychedelic trials. Rapid breathing can induce hyperventilation syndrome, panic, or even loss of consciousness in susceptible individuals. The study's findings are based on self-reported experiences from trained professionals in a controlled workshop setting, which may not generalize to broader or more vulnerable populations. Crucially, the study was exploratory and not a randomized controlled trial; efficacy and safety remain unproven in clinical populations. The risk–benefit profile of HVB must be rigorously evaluated in larger, controlled studies before clinical adoption. A real-world failure mode worth noting is the potential for unregulated or poorly supervised breathwork sessions to lead to adverse psychological or physical outcomes, especially if adopted outside of clinical oversight.

Future Directions: Integrating HVB Into Psychedelic Science and Practice

HVB offers a promising, scalable, and legally accessible model for inducing psychedelic-like states, but its role in clinical practice and research will depend on the outcomes of future controlled trials. Researchers should prioritize studies that directly compare HVB with pharmacological psychedelics, assess long-term outcomes, and identify which patient populations may benefit—or be harmed—by such interventions. Policymakers and institutional review boards may also need to develop new guidelines for non-pharmacological altered state research, given HVB's unique risk and benefit profile. As the field moves forward, integrating HVB into the toolkit of psychedelic science could help clarify the active ingredients of therapeutic change and broaden access to transformative experiences under safe, evidence-based conditions.

How we research: This article was written and reviewed by Dr. Alex M. Greene, PhD (neuroscience, clinical research editor), on 2026-09-18. Primary source: OpenAlex study record.